Rory’s Always On Newsletter • 595 implied HN points • 18 Oct 24
- Exenatide, a drug initially hopeful for slowing Parkinson's, failed in its final trial. This has left many in the Parkinson's community feeling uncertain and disappointed.
- Researchers are still figuring out why the drug worked in earlier tests but failed later. They need more data to understand if it was because the drug didn't reach the brain or if it just wasn't effective.
- The failure of Exenatide could make it harder for other similar drugs to get funding for trials. Meanwhile, experts emphasize that exercise remains a reliable way to manage Parkinson's symptoms.